2022
Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
Thompson H, Hogan A, Walker P, Winskill P, Zongo I, Sagara I, Tinto H, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B, Cairns M, Ghani A. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. The Lancet Global Health 2022, 10: e1782-e1792. PMID: 36400084, DOI: 10.1016/s2214-109x(22)00416-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionSeasonal transmission settingsS vaccinationTransmission settingsTransmission seasonFull therapeutic coursePhase 3b trialSevere malaria outcomesUK Medical Research CouncilEstimates of casesDuration of protectionMalaria transmission intensityEntomological inoculation rateGreater absolute reductionMedical Research CouncilTransmission intensitySignificant additional protectionAge-based strategiesMalaria outcomesClinical malariaMalaria chemopreventionVaccination scheduleMalaria vaccineClinical incidenceClinical trialsSmall-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial
Abbeddou S, Jimenez E, Hess S, Somé J, Ouédraogo J, Brown K. Small-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial. European Journal Of Nutrition 2022, 61: 4107-4120. PMID: 35829783, PMCID: PMC9596589, DOI: 10.1007/s00394-022-02936-6.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsNon-intervention cohortLipid-based nutrient supplementsIntervention cohortIntervention groupCluster-randomized community trialFat-free mass accretionAdditional zinc supplementationFat depositionTrial registrationThe studyCluster-randomized trial designDispersible tabletsMonths of ageExcessive fat depositionMorbidity treatmentNIC childrenNutrient supplementsBurkinabe childrenUS National InstitutesObesity riskZinc supplementationClinical trialsCommunity trialFat massTrial design
2021
Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus
Hema-Ouangraoua S, Tranchot-Diallo J, Zongo I, Kabore N, Nikièma F, Yerbanga R, Tinto H, Chandramohan D, Ouedraogo G, Greenwood B, Ouedraogo J. Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus. PLOS ONE 2021, 16: e0257190. PMID: 34644317, PMCID: PMC8513893, DOI: 10.1371/journal.pone.0257190.Peer-Reviewed Original ResearchConceptsAdministration of azithromycinSerious illnessS. aureusEffectiveness of azithromycinMalaria transmission seasonVulnerable pediatric populationS. aureus isolatesImpact of azithromycinNasal carriageRespiratory infectionsSulfadoxine-pyrimethaminePediatric populationClinical trialsAzithromycin resistanceNasal swabsAureus isolatesTransmission seasonAzithromycinPrevalent strainsMajor causeAdministrationPlaceboStaphylococcus aureusChildrenIllnessEffectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries
Cairns M, Ceesay S, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi J, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo J, Dicko A, Ndiaye J, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. PLOS Medicine 2021, 18: e1003727. PMID: 34495978, PMCID: PMC8457484, DOI: 10.1371/journal.pmed.1003727.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAge FactorsAmodiaquineAntimalarialsCase-Control StudiesChild, PreschoolCommunicable Disease ControlDrug CombinationsFemaleHumansIncidenceInfantMalaria, FalciparumMaleParasite LoadPlasmodium falciparumProgram EvaluationPyrimethamineRisk AssessmentRisk FactorsSeasonsSulfadoxineTime FactorsTreatment OutcomeConceptsSeasonal malaria chemopreventionCase-control studyClinical malariaOdds ratioClinical trialsNational Malaria Control ProgrammeClinical malaria incidenceIndividual case-control studiesIncidence rate ratiosHigh protective efficacyConditional logistic regressionMalaria control activitiesMalaria control programmesPersonal protectionCase-control designChemoprevention treatmentMalaria chemopreventionSevere malariaSMC treatmentMean agePrimary exposureProtective efficacyResidual confoundingHealth facilitiesParasite densityHepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubinThe Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali
Phiri M, Cairns M, Zongo I, Nikiema F, Diarra M, Yerbanga R, Barry A, Tapily A, Coumare S, Thera I, Kuepfer I, Milligan P, Tinto H, Dicko A, Ouédraogo J, Greenwood B, Chandramohan D, Sagara I. The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali. Clinical Infectious Diseases 2021, 73: e2379-e2386. PMID: 33417683, PMCID: PMC8492219, DOI: 10.1093/cid/ciaa1905.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMass drug administrationMalaria chemopreventionPlacebo-controlled trialEvidence of protectionDuration of protectionHospital admissionAcute respiratoryIllness episodesWeeks postadministrationClinical trialsSkin infectionsSkin conditionsDrug AdministrationProfile of protectionAzithromycinPoisson regressionChild survivalSecondary analysisBurkina FasoDifferent causesExtent of protectionChemopreventionMalariaAdministration
2020
The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalence
2019
OC 8721 WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPLICATED MALARIA IN WEST AND CENTRAL AFRICA
Djimde A, Grobusch M, Zoleko Manego R, Mombo-Ngoma G, Picot S, Sagara I, Sutherland C, Kone A, Doumbo O, Pedro Gil J, Björkman A, Borrmann S, Soulama I, Fofana B, Duparc S, Dicko A, Hughes D, Winnips C, Sirima S, Adehossi E, Ouedraogo J, Dembele L, Zongo I, Biguenet S, Ilboudo-Sanogo E, Fofana A. OC 8721 WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPLICATED MALARIA IN WEST AND CENTRAL AFRICA. BMJ Global Health 2019, 4: a17.3-a18. DOI: 10.1136/bmjgh-2019-edc.43.Peer-Reviewed Original ResearchTrial programNew antimalarial drug combinationMajor public health problemAntimalarial drug combinationsClinical trial programPublic health problemYears of ageNew antimalarial drugsClinical research teamRegulatory health authoritiesNew antimalarial treatmentsUncomplicated malariaFalciparum malariaAntimalarial treatmentPatient adherenceCombination therapySingle dosesClinical trialsClinical studiesKAF156Drug combinationsArtemisinin derivativesClinical developmentDrug development pipelineHealth problems
2016
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valéa I, Sorgho H, Owusu-Dabo E, Ouédraogo J, Guiguemdé T, Tinto H. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE 2016, 11: e0151565. PMID: 27031231, PMCID: PMC4816516, DOI: 10.1371/journal.pone.0151565.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsBurkina FasoChildDrug CombinationsEthanolaminesFemaleFluorenesGene FrequencyGenotypeHost-Parasite InteractionsHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMultivariate AnalysisParasitemiaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsTreatment OutcomeConceptsPfmdr1 allelesTreatment failureArtemether-lumefantrine therapyPfcrt K76TSingle nucleotide polymorphismsRestriction fragment length polymorphism methodFragment length polymorphism methodPotential beneficial effectsLength polymorphism methodArtesunate-AmodiaquineRecurrent parasitaemiaTreatment regimenACT resistanceCombination therapyK76TPfmdr1 geneClinical trialsTreatment outcomesMultivariate analysisDay 0PfcrtMalaria controlBlood spotsBeneficial effectsPolymorphism method
2015
Comparison of methods to assess adherence to small‐quantity lipid‐based nutrient supplements (SQ‐LNS) and dispersible tablets among young Burkinabé children participating in a community‐based intervention trial
Abbeddou S, Hess S, Yakes Jimenez E, Somé J, Vosti S, Guissou R, Ouédraogo J, Brown K. Comparison of methods to assess adherence to small‐quantity lipid‐based nutrient supplements (SQ‐LNS) and dispersible tablets among young Burkinabé children participating in a community‐based intervention trial. Maternal And Child Nutrition 2015, 11: 90-104. PMID: 25521188, PMCID: PMC6860357, DOI: 10.1111/mcn.12162.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsPlasma zinc concentrationDispersible tabletsLipid-based nutrient supplementsCaregiver-reported adherenceMonths of supplementationDisappearance rateMonths of ageSubgroup of childrenWeekly adherenceIntervention trialsClinical trialsLow adherenceSupplementation trialAdherence dataHome visitsCaregiver interviewsZinc tabletsLack of changeChildren 11Zinc concentrationsStudy outcomesObservation periodAdherenceMonthsSafety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilitiesAnemia And Iron Supplementation Is Not Associated with Malaria in Young Burkinabe Children
Some J, Abbeddou S, Jimenez E, Ouedraogo Z, Ouedraogo J, Brown K, Hess S. Anemia And Iron Supplementation Is Not Associated with Malaria in Young Burkinabe Children. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.757.9.Peer-Reviewed Original ResearchLipid-based nutrient supplementsRapid diagnostic testsYoung Burkinabe childrenBurkinabe childrenIron supplementationFe supplementsPositive malaria rapid diagnostic testPositive rapid diagnostic testMalaria rapid diagnostic testsRandomized clinical trialsIncidence of malariaMo of ageMalaria episodesAntimalarial treatmentSevere anemiaModerate anemiaClinical trialsAnthelminthic treatmentHome visitsMalaria diagnosisHemoglobin concentrationMalaria incidenceIron treatmentDiagnostic testsMalaria
2014
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquineAdherence to small‐quantity lipid based nutrient supplement among young Burkinabe children (624.19)
Abbeddou S, Hess S, Jimenez E, Somé J, Guissou R, Ouedraogo Z, Vosti S, Ouedraogo J, Brown K. Adherence to small‐quantity lipid based nutrient supplement among young Burkinabe children (624.19). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.624.19.Peer-Reviewed Original ResearchSQ-LNSDays/weekHome visitsSmall-quantity lipid-based nutrient supplementsLipid-based nutrient supplementsSmall-Quantity LipidYoung Burkinabe childrenRandomized clinical trialsReporting of adherenceWeekly home visitsDisappearance rateWeekly adherenceNutrient supplementsBurkinabe childrenClinical trialsSupplementation regimensCaregiver interviewsFull doseHome ObservationMelinda Gates FoundationOlder childrenObservation periodAdherenceChildrenGrant funding sources